These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35612924)

  • 21. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial.
    Kokabi N; Webster LA; Elsayed M; Switchenko JM; Chen B; Brandon D; Galt J; Sethi I; Cristescu M; Kappadath SC; Schuster DM
    J Vasc Interv Radiol; 2022 Dec; 33(12):1578-1587.e5. PubMed ID: 36075560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative comparison of pre-therapy
    Knešaurek K; Tuli A; Pasik SD; Heiba S; Kostakoglu L
    Eur J Radiol; 2018 Dec; 109():57-61. PubMed ID: 30527312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
    Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
    J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres.
    Lambert B; Mertens J; Sturm EJ; Stienaers S; Defreyne L; D'Asseler Y
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2328-33. PubMed ID: 20683591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.
    Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT.
    Brunson CP; McGregor HJ; Hennemeyer CT; Patel MV; Woodhead GJ; Young SJ
    J Vasc Interv Radiol; 2024 Jan; 35(1):94-101. PubMed ID: 37783268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of
    Allred JD; Niedbala J; Mikell JK; Owen D; Frey KA; Dewaraja YK
    EJNMMI Res; 2018 Jun; 8(1):50. PubMed ID: 29904808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accurate non-tumoral 99mTc-MAA absorbed dose prediction to plan optimized activities in liver radioembolization using resin microspheres.
    d'Abadie P; Walrand S; Hesse M; Amini N; Lhommel R; Sawadogo K; Jamar F
    Phys Med; 2021 Sep; 89():250-257. PubMed ID: 34438353
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Debebe SA; Adjouadi M; Gulec SA; Franquiz J; McGoron AJ
    J Appl Clin Med Phys; 2019 Feb; 20(2):30-42. PubMed ID: 30628156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors.
    Bilbao JI; Garrastachu P; Herráiz MJ; Rodríguez M; Iñarrairaegui M; Rodríguez J; Hernández C; de la Cuesta AM; Arbizu J; Sangro B
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):523-31. PubMed ID: 19841973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Mar; 56(3):333-8. PubMed ID: 25655623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 99mTc-MAA/ 90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization.
    Ahmadzadehfar H; Sabet A; Muckle M; Wilhelm K; Reichmann K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1281-8. PubMed ID: 21359611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.